Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca reports positive results from Phase III trial of exenatide in type 2 diabetes British drug-maker AstraZeneca has reported positive results from a 28-week Phase III trial of exenatide to treat adult patients with type 2 diabetes. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Phosplatin starts dosing in Phase I trial of PT-112 for solid tumors
By PBR Staff Writer
Phosplatin Therapeutics has dosed the first group of patients in its Phase I first-in-human clinical trial of PT-112, the lead therapeutic candidate among its phosphaplatin family of molecules, to treat solid tumors.
News
Genervon reports Phase IIa trial results of GM6 drug in ALS and PD
By PBR Staff Writer
Genervon Biopharmaceuticals has reported results from its two Phase IIa double blinded, randomized, placebo controlled clinical trials of its drug candidate GM6 in patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s disease (PD).
News

Contract Research

Revalesio's RNS60 shows promise in treating Alzheimer's disease and other dementias
Revalesio and Rush University Medical Center's Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer's disease and other forms of dementia by protecting neuronal function, restoring neuronal connections and promoting neuronal plasticity.
News
Cannabics Pharmaceuticals receives Cannabinoid R&D lab certification in Israel
Cannabics Pharmaceuticals has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.
News

Contract Services

NewLink, Genentech ink licensing deal for development of NLG919
By PBR Staff Writer
US-based biopharmaceutical firm NewLink Genetics has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche, to develop its IDO pathway inhibitor NLG919.
News
Enanta Pharmaceuticals provides update on its collaboration agreement with AbbVie
Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, has announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus (HCV) being developed in Enanta’s collaboration with AbbVie.
News